Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-lb: Relationship to adherence to treatment

Abstract

This study, conducted in three separate outpatient health care delivery settings, examined the therapeutic expectations of patients with multiple sclerosis (MS) before they initiated interferon beta-lb therapy, the results of current educational procedures to correct unrealistic expectations, and the relationship between post-education expectations and discontinuing therapy. Ninety-nine consecutive patients were seen in a university based outpatient MS clinic, an academic group practice outpatient MS clinic, or a health maintenance organization outpatient neurology clinic Before the educational sessions, 57% of the patients expressed unrealistically optimistic expectations regarding reduction in attack rate and 34% expressed unrealistically optimistic expectations regarding improvement in functional status. Educational procedures significantly altered unrealistic expectations but the results were sub-optimal since 33% of the patients maintained overly optimistic expectations regarding reduction in attack rate. Post-education unrealistic expectations of improvement in functional status were significantly related to discontinuing therapy within 6 months. Three adverse effects of therapy also were related independently to adherence to treatment depression and flu-like symptoms were related to discontinuing therapy while soreness at injection site was related to continuing therapy.

Keywords

multiple sclerosis interferon beta l-b adherence compliance side effects

Get full access to this article

View all access options for this article.

References

1 Goodkin DE . (1994) Drug profile: Interferon beta-lb. Lancet 344: 57–1060.

2 INFB. MS Study Group. (1993) Interferon beta-l-b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655–661.

3 INFB. MS Study Group. (1993) Interferon beta-l-b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter randomized double-blind placebo-controlled trial. Neurology 43: 662–667.

4 Neilley LK et al. (1995) Side effect profile of interferon beta 1-b (Betaseron). Neurology 45: A437.

5 Goodkin DE . (1996) Interferon beta treatment for multiple sclerosis: Persisting question. Multiple Sclerosis 1: 321–324.

6 O'Brien MK , Petrie K , Raeburn J. (1992) Adherence to medication regimens: Updating a complex medical issue. Medical Care Review 49: 435–445.

7 Becker MH et al. (1979) Patient perceptions and compliance: Recent studies of the health belief model. Compliance in Health Care. Edited by RB Haynes , DW Taylor , DL Sachett . Baltimore MD: Johns Hopkins University Press.

8 Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis. Ann Neurol 13: 227–231.

9 Mohr DC et al. (1995) Expectations of multiple sclerosis patients initiating Betaseron therapy [abstract]. Neurology 45(suppl 4): 197.

10.

10 Jacobs LD et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis Annals of Neurology, in press.

11.

11 Johnson KP et al. (1995) Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III, multicenter double-blind, placebo-controlled trial. Neurology 45: 1268–1276.